Form 4: Arrowhead Pharmaceuticals CEO Acquires Shares in Lieu of Bonus

Christopher Anzalone, CEO of Arrowhead Pharmaceuticals, acquired 9,550 shares of common stock on February 7, 2025, in lieu of a portion of his year-end cash bonus.

Summary

• On February 7, 2025, Christopher Anzalone, the CEO of Arrowhead Pharmaceuticals, acquired 9,550 shares of the company's common stock.
• The acquisition was made in lieu of a portion of his year-end cash bonus.
• The price per share was $20.1.
• Following the transaction, Anzalone beneficially owns 3,773,802 shares, including shares underlying Restricted Stock Units subject to vesting conditions.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The CEO taking equity in lieu of cash is generally seen as a positive sign, indicating confidence in the company's future. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The CEO's decision to take equity in lieu of cash may signal confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• Shareholders may view the CEO's stock acquisition as a positive signal.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Christopher Anzalone, CEO, stock acquisition, Form 4, beneficial ownership, equity compensation, Restricted Stock Units